hervcov
“Understand the pathogenic role of HERV-W envelope protein and develop novel prognostic markers and therapeutic targets for personalized treatment of COVID-19-associated syndromes”

PROJECT UPDATES

  • 4TH LONG COVID INTERNATIONAL CONFERENCE 2026: HERVCOV researchers are expected to take part in the 4th Long COVID International Conference 2026, which will be held in Nice, France, on 12–13 November 2026. Further information is available in the Talks section.
  • THE 2026 CONSORTIUM MEETING (Toulose):
    This year, France will host the annual consortium meeting, which will take place at the Institut des Maladies Métaboliques et Cardiovasculaires. On 6–7 July, partners will take part in internal meetings dedicated to sharing the scientific progress achieved over the past year and discussing the next steps of the project. On the final day, participants will have the opportunity to join public activities, offering a chance to meet and interact with project researchers and learn more about Long COVID and ongoing research efforts.
  •  NEW PUBBLICATIONS AVAILABLE:  i) HERV-K HML-2 transcriptional profiling and splicing pattern unveiled by direct single-molecule long-read RNA squencing; ii) CD169+ and HLA-DR+ extracellular vesicles are highly represented in human plasma and dynamically expressed in SARS-CoV-2 infection and long COVID-associated sequelae, visit publication section for the full article.
Download the press release

Consortium Meetings


These are the goals of a project involving researchers from 5 different EU countries. This study has already produced evidence for the induction of a specific protein during COVID-19 disease. New information to guide predictive and personalized medicine may be obtained in the near future thanks to this discovery.